Navigation Links
Regulus Reports Third Quarter 2013 Financial Results and Recent Highlights
Date:11/13/2013

idates for clinical development in 2013, be positioned to file its first applications with regulatory authorities by the first half of 2014 and maintain a strong year-end cash position to support these goals. 

Regulus has demonstrated excellent progress on its 'Road to the Clinic' Strategy. In May, Regulus nominated its first microRNA candidate for clinical development, RG-101, a GalNAc-conjugated microRNA antagonist or anti-miR, which targets miR-122 for the treatment of HCV.  Regulus expects to file its first application with regulatory authorities for RG-101 in the near term and expects to commence clinical studies in man in early 2014.  Additionally, Regulus' strong financial position continues to support these stated goals and the Company continues to expect to end 2013 with approximately $110 million in cash, cash equivalents and short-term investments.  Lastly, Regulus expects that the second microRNA candidate to be nominated for clinical development by the end of the year may come from the miR-21 fibrosis program.

About RG-101 for the Treatment of HCVRG-101 is a key program in Regulus' 'Road to the Clinic' Strategy for 2013, in which the Company expects to nominate two microRNA candidates for clinical development, be positioned to file its first applications with regulatory authorities by the first half of 2014 and maintain a strong year-end cash position to support these goals.  RG-101 was the first microRNA candidate nominated for clinical development under this strategy.

microRNA-122 (miR-122) is the most abundant microRNA in hepatocytes and is a critical host factor for survival and replication of all know HCV genotypes.  RG-101 is a novel anti-miR-122 oligonucleotide therapeutic that is effectively targeted to hepatocytes for the treatment of HCV through conjugation to GalNAc, a carbohydrate-based chemistry approach for asialoglycoprotein receptor-mediated delivery of oligonucleotides to hepatocyte c
'/>"/>

SOURCE Regulus Therapeutics Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine technology :

1. Regulus Presents Positive Preclinical Data Demonstrating that microRNA-21 Plays an Important Role in Alport Syndrome
2. Regulus Announces Timing for Third Quarter 2013 Financial Results Webcast and Conference Call
3. Regulus Announces Significant Progress in Strategic Alliance with AstraZeneca and Selection of a New Pre-Clinically Validated microRNA Oncology Target
4. Regulus Reports Second Quarter 2013 Financial Results and Recent Highlights
5. Regulus Announces Timing for Second Quarter 2013 Financial Results Webcast and Conference Call
6. Regulus Names Stelios Papadopoulos, Ph.D. as Chairman of its Board of Directors
7. Regulus to Present at Deutsche Bank 38th Annual Healthcare Conference
8. Regulus Provides Update on Road to the Clinic Strategy and Reports First Quarter 2013 Financial Results and Recent Highlights
9. Regulus Announces Timing for First Quarter 2013 Financial Results Webcast and Conference Call
10. Regulus Appoints William H. Rastetter, Ph.D. to its Board of Directors
11. Regulus to Present at Future Leaders in the Biotech Industry Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... Antigen Discovery Inc. (ADi), a privately held ... the receipt of a National Institutes of Health (NIH) ... Institute of Dental and Craniofacial Research (NIDCR). The one-year ... Protein Microarray Chip, which will contain every protein in ... in the development of safe and effective vaccines and ...
(Date:10/22/2014)... , Oct. 22, 2014 AVACEN Medical announced ... received 510 (k) OTC clearance by the U.S. Food ... to be marketed over the Internet for: the ... spasms; and minor strains and sprains . ... AVACEN 100 (MSRP $2495) is a sophisticated medical device ...
(Date:10/22/2014)... Oct. 21, 2014   BioNano Genomics , ... genomics research centers to purchase an Irys™ System ... National Cancer Institute (NCI), NIH Intramural Sequencing Center (NISC) ... Irys, obtaining a comprehensive view of a genome ... (NGS) does not deliver the scalability or reliability ...
Breaking Medicine Technology:Biomarker Discovery Company, Antigen Discovery Inc., Awarded an NIH Phase I Small Business Innovation Research Grant to Develop a Pan-HIV Protein Microarray Chip 2AVACEN Medical Announces FDA Clearance of First Medical Device with Internal Game Mode 2BioNano's Irys System Adopted by Leading Genomics Centers for Comprehensive Detection of Human Genome Structural Variation 2BioNano's Irys System Adopted by Leading Genomics Centers for Comprehensive Detection of Human Genome Structural Variation 3
(Date:10/22/2014)... (HealthDay News) -- The United States is now ... nations of West Africa land at one of ... with the virus. In a statement released ... 94 percent of air passengers from Guinea, Liberia ... these five airports -- New York City,s Kennedy ...
(Date:10/22/2014)... During the Western United States’ worst ... dangerously low, Southern Oregon’s water is proving resistant to ... lowest mountain snow pack on record in 2014, remain ... autumn.* That was the observation of journalist-hikers Art Bernstein ... Southern Oregon,” during an interview with water advocate Sharon ...
(Date:10/22/2014)... Viejo, CA (PRWEB) October 22, 2014 ... Jay Cormier, Sr. Vice President of Sales, will be ... the upcoming Meetings Technology Expo on October 28, at ... also be hosting a booth as well as a ... how Lintelus Meeting can create a more engaging event ...
(Date:10/22/2014)... News) -- Two sisters in high school have developed ... and Medha Krishen use electronic stethoscopes, which electronically amplify ... breathing patterns or heartbeats. Ilina, a senior at ... find a way to detect early lung damage in ... stethoscope, Ilina recorded one breath cycle each from 16 ...
(Date:10/22/2014)... Dennis Thompson HealthDay Reporter ... cameraman who was diagnosed with Ebola while working for NBC ... and can leave the special isolation unit at Nebraska Medical Center ... weeks, the hospital said Tuesday. A blood test confirmed by ... Mukpo, 33, can head home to Providence, R.I., NBC News ...
Breaking Medicine News(10 mins):Health News:Passengers From Ebola-Affected Countries Must Land at Designated U.S. Airports 2Health News:Passengers From Ebola-Affected Countries Must Land at Designated U.S. Airports 3Health News:Southern Oregon Is West’s Most Drought Proof Fresh Water Region Say Hiking Guide Authors 2Health News:Southern Oregon Is West’s Most Drought Proof Fresh Water Region Say Hiking Guide Authors 3Health News:Southern Oregon Is West’s Most Drought Proof Fresh Water Region Say Hiking Guide Authors 4Health News:Jay Cormier, Sr. Vice President of Sales for Lintelus, Speaks about Event Technology Integration at Meetings Technology Expo in NYC 2Health News:Teen Sisters Develop Ways to Measure Lung, Heart Damage 2Health News:U.S. Cameraman Treated for Ebola 'Free' of the Virus 2Health News:U.S. Cameraman Treated for Ebola 'Free' of the Virus 3
... World Health Organisation (WHO) has said that the risk of ... In a report analyzing 205 infections that occurred from December ... have peaked in winter and spring months, the WHO also ... this year or early next year. "If this pattern continues, ...
... World Food Programme (WFP) announced on Wednesday that as ... acute food shortage in Southern Africa. //WFP executive director ... recent years, there was a distribution problem. ... to eat," he said. "Food and good nutrition are ...
... Noel Colina, the executive director at the Institute for Occupation ... night shifts are more prone //to develop breast cancer. Citing ... said that a number of women were taking up work ... 6 a.m. ,This type of work usually done ...
... A protein that allows breast cancer cells to evade the body’s ... according to a study by Keck School of Medicine of USC ... issue of the American Journal of Pathology, is the first to ... of cells – functions. ,“The important aspect of ...
... Glucosamine, a substance used in treating arthritis was now found ... UV damaged skin and preventing the //formation of new age ... Harvard Medical School have reported that the more stable n-acetyl ... cells thus proved its effect in UV-related skin damage treatment. ...
... Shire was the foremost patch medication approved to treat ... of methylphenidate - DAYTRANA, is now available in pharmacies ... 20 mg and 30 mg. ,'The availability of DAYTRANA, ... and parents with a new, practical way to individualize ...
Cached Medicine News:Health News:Researchers Investigate Protein that Protects Tumors 2Health News:Study Finds - UV Damaged Skin could be Possibly Treated with Glucosamine 2Health News:Study Finds - UV Damaged Skin could be Possibly Treated with Glucosamine 3Health News:Shire Developed DAYTRANA – The First Medication to Treat ADHD Symptom 2Health News:Shire Developed DAYTRANA – The First Medication to Treat ADHD Symptom 3Health News:Shire Developed DAYTRANA – The First Medication to Treat ADHD Symptom 4
McPherson titanium tying forceps which is 5 mm long, smooth jaws and straight. Used for 8-0 to 11-0 sutures....
Straight shafts with 5 mm tying platform. Wide handle with dull finish. Overall length 4.3 inches....
Delicate curved tying forcep with round handle is excellent for all fine suturing techniques. Useful for corneal transplants where delicate control is required....
Angled Castroviejo handle. Manufactured in titanium. Overall length 4.2 inches....
Medicine Products: